

Global HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

Market Report | 2023-04-16 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

Global HUMIRA (Adalimumab) Drug Market Outlook

The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2023-2031, driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment. The market is projected to grow at a CAGR of 1% during the forecast period.

HUMIRA (Adalimumab) Drug Market: Introduction

The global HUMIRA (Adalimumab) drug market is a rapidly growing market that provides treatment for various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by suppressing the immune system and reducing inflammation. It is a widely used drug and is considered as a first-line treatment option for many autoimmune diseases. The increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment are the key drivers of the market.

Expert Market Research has released a comprehensive report on the global HUMIRA (Adalimumab) drug market, which provides an in-depth analysis of the market and its segments. HUMIRA is a widely used drug for the treatment of various autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The report covers the market for HUMIRA and provides a detailed analysis of the market size, growth, and trends. The market is highly competitive with several key players involved in the market, focusing on developing new drugs and therapies to strengthen their position in the market.

HUMIRA (Adalimumab) Drug Market- Application and Usage

The global HUMIRA (Adalimumab) drug market is used for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by targeting and reducing the activity of a specific protein called tumor necrosis factor-alpha (TNF-alpha) that is involved in causing inflammation in the body. The drug is administered subcutaneously or intravenously, depending on the condition being treated.

Rheumatoid arthritis is one of the primary applications of HUMIRA, and it is widely used as a first-line treatment option for this

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

condition. It is also used for the treatment of psoriasis, which is a chronic skin condition characterized by red, scaly patches on the skin. HUMIRA can provide relief from the symptoms of psoriasis by reducing inflammation in the skin.

In addition to rheumatoid arthritis and psoriasis, HUMIRA is also used for the treatment of Crohn's disease and ulcerative colitis. These are chronic inflammatory bowel diseases that affect the digestive system. HUMIRA can help reduce inflammation in the digestive tract and improve symptoms such as abdominal pain, diarrhea, and rectal bleeding.

HUMIRA (ADALIMUMAB) Drug Market Segmentations

The market can be categorised into indication, type, dosage strength, drug type, distribution channel, and route of administration.

Market Breakup by Indication

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Chronic Plaque Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Others

Market Breakup by Type

- Biologics
- Biosimilars
- Adalimumab-ATTO
- Adalimumab-BWWD
- Adalimumab-ADBIM
- Adalimumab-ADAZ
- Adalimumab-FKJP
- Adalimumab-AFZB
- Others

Market Breakup by Dosage Strength

- 40MG/0.4ML
- 80MG/0.8ML
- 20MG/0.4ML
- 10MG/0.1ML
- Others

Market Breakup by Drug Type

- Branded
- Generics
- Amjevita
- Hyrimoz
- Hulio
- Others

Market Breakup by Distribution Channels

- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Breakup by Route of Administration

- Parenteral
- Oral
- Others

Market Breakup by Region

- North America
 - ?□United States of America
 - ?□Canada
- Europe
 - ?□United Kingdom
 - ?□Germany
 - ?□France
 - ?□Italy
 - ?□Others
- Asia Pacific
 - ?□China
 - ?□Japan
 - ?□India
 - ?□ASEAN
 - ?□Australia
 - ?□Others
- Latin America
 - ?□Brazil
 - ?□Argentina
 - ?□Mexico
 - ?□Others
- Middle East and Africa
 - ?□Saudi Arabia
 - ?□United Arab Emirates
 - ?□Nigeria
 - ?□South Africa
 - ?□Others

HUMIRA (Adalimumab) drug Market Scenario

The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2023-2031. The market is driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment.

North America dominates the HUMIRA drug market, followed by Europe and the Asia Pacific region. The high prevalence of autoimmune diseases and the availability of advanced healthcare infrastructure are driving the growth of the market in North America. Europe is also a significant market for HUMIRA, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

In addition, the COVID-19 pandemic has also affected the HUMIRA drug market, with disruptions in supply chain and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

manufacturing activities. However, the market is expected to recover in the post-pandemic period, driven by the increasing demand for effective treatments for autoimmune diseases.

Overall, the global HUMIRA (Adalimumab) drug market is expected to continue its growth trajectory during the forecast period, offering numerous opportunities for key players and investors in the industry.

Key Players in the Global HUMIRA (Adalimumab) drug Market

The report gives an in-depth analysis of the key players involved in the HUMIRA (Adalimumab) drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- [] AbbVie Inc.
- [] Amgen Inc.
- [] Fresenius Kabi AG
- [] Celltrion Healthcare Co Ltd
- [] Alvotect Ehf.
- [] Bio-Thera Solutions Ltd.
- [] Zydus Lifesciences Limited
- [] Hetero Healthcare Ltd.
- [] Innovent Biologics, Inc.
- [] Novartis International AG
- [] Reliance Life Sciences Pvt. Ltd.
- [] Samsung C&T Corporation
- [] Terumo Corp.
- [] Torrent Pharmaceuticals Ltd.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 HUMIRA (Adalimumab Drug) Overview
 - 4.1 Drug Overview
 - 4.1.1 Pharmacodynamics
 - 4.1.2 Pharmacokinetics
 - 4.1.3 Adverse Events
- 5 Patient Profile
 - 5.1 Patient Profile Overview
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework
 - 6.1 Emerging Therapies and Clinical Trials Synopsis
 - 6.2 Patent Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.1 Patent Overview
 - 6.2.1.1 Patent Status and Expiry
 - 6.2.1.2 Timelines from Drug Development to Commercial Launch
 - 6.2.1.3 New Drug Application
 - 6.2.1.3.1 Documentation and Approval Process
- 6.3 Cost of Treatment
- 6.4 Investment Scenarios
- 6.5 Regulatory Framework
 - 6.5.1 Regulatory Overview
 - 6.5.1.1 US FDA
 - 6.5.1.2 EU EMA
 - 6.5.1.3 INDIA CDSCO
 - 6.5.1.4 JAPAN PMDA
 - 6.5.1.5 Others
- 7 Challenges and Unmet Need
 - 7.1 Treatment Pathway Challenges
 - 7.2 Compliance and Drop-Out Rate
 - 7.3 Awareness and Prevention Gaps
- 8 Global HUMIRA (Adalimumab Drug) Market
 - 8.1 Global HUMIRA (Adalimumab Drug) Market Overview
 - 8.2 Global HUMIRA (Adalimumab Drug) Market Analysis
 - 8.2.1 Market Overview
 - 8.2.1.1 Global HUMIRA (Adalimumab Drug) Market Historical Value (2016-2022)
 - 8.2.1.2 Global HUMIRA (Adalimumab Drug) Market Forecast Value (2023-2031)
 - 8.3 Global HUMIRA (Adalimumab Drug) Market by Indication
 - 8.3.1 Market Overview
 - 8.3.1.1 Rheumatoid Arthritis
 - 8.3.1.2 Ankylosing Spondylitis
 - 8.3.1.3 Chronic Plaque Psoriasis
 - 8.3.1.4 Crohn's Disease
 - 8.3.1.5 Ulcerative Colitis
 - 8.3.1.6 Psoriatic Arthritis
 - 8.3.1.7 Others
 - 8.4 Global HUMIRA (Adalimumab Drug) Market by Type
 - 8.4.1 Market Overview
 - 8.4.1.1 Biologics
 - 8.4.1.2 Biosimilars
 - 8.4.1.2.1 Adalimumab-ATTO
 - 8.4.1.2.2 Adalimumab-BWWD
 - 8.4.1.2.3 Adalimumab-ADBIM
 - 8.4.1.2.4 Adalimumab-ADAZ
 - 8.4.1.2.5 Adalimumab-FKJP
 - 8.4.1.2.6 Adalimumab-AFZB
 - 8.4.1.2.7 Others
 - 8.5 Global HUMIRA (Adalimumab Drug) Market by Dosage Strength
 - 8.5.1 Market Overview
 - 8.5.1.1 40MG/0.4ML

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.1.2 80MG/0.8ML
- 8.5.1.3 20MG/0.4ML
- 8.5.1.4 10MG/0.1ML
- 8.5.1.5 Others
- 8.6 Global HUMIRA (Adalimumab Drug) Market by Drug Type
 - 8.6.1 Market Overview
 - 8.6.1.1 Branded
 - 8.6.1.2 Generics
 - 8.6.1.2.1 Amjevita
 - 8.6.1.2.2 Hyrimoz
 - 8.6.1.2.3 Hulio
 - 8.6.1.2.4 Others
- 8.7 Global HUMIRA (Adalimumab Drug) Market by Route of Administration
 - 8.7.1 Market Overview
 - 8.7.1.1 Parenteral
 - 8.7.1.2 Oral
 - 8.7.1.3 Others
- 8.8 Global HUMIRA (Adalimumab Drug) Market by Distribution Channels
 - 8.8.1 Market Overview
 - 8.8.1.1 Hospital Based Pharmacies
 - 8.8.1.2 Online Pharmacies
 - 8.8.1.3 Retail Pharmacies
- 8.9 Global HUMIRA (Adalimumab Drug) Market by Region
 - 8.9.1 Market Overview
 - 8.9.1.1 North America
 - 8.9.1.2 Europe
 - 8.9.1.3 Asia Pacific
 - 8.9.1.4 Latin America
 - 8.9.1.5 Middle East and Africa
- 9 North America HUMIRA (Adalimumab Drug) Market
 - 9.1 Market Share by Country
 - 9.2 United States of America
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 Canada
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe HUMIRA (Adalimumab Drug) Market
 - 10.1 Market Share by Country
 - 10.2 United Kingdom
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Germany
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
 - 10.4 France
 - 10.4.1 Historical Trend (2016-2022)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.2 Forecast Trend (2023-2031)
- 10.5 Italy
 - 10.5.1 Historical Trend (2016-2022)
 - 10.5.2 Forecast Trend (2023-2031)
- 10.6 Others
- 11 Asia Pacific HUMIRA (Adalimumab Drug) Market
 - 11.1 Market Share by Country
 - 11.2 China
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)
 - 11.3 Japan
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
 - 11.4 India
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
 - 11.5 ASEAN
 - 11.5.1 Historical Trend (2016-2022)
 - 11.5.2 Forecast Trend (2023-2031)
 - 11.6 Australia
 - 11.6.1 Historical Trend (2016-2022)
 - 11.6.2 Forecast Trend (2023-2031)
 - 11.7 Others
- 12 Latin America HUMIRA (Adalimumab Drug) Market
 - 12.1 Market Share by Country
 - 12.2 Brazil
 - 12.2.1 Historical Trend (2016-2022)
 - 12.2.2 Forecast Trend (2023-2031)
 - 12.3 Argentina
 - 12.3.1 Historical Trend (2016-2022)
 - 12.3.2 Forecast Trend (2023-2031)
 - 12.4 Mexico
 - 12.4.1 Historical Trend (2016-2022)
 - 12.4.2 Forecast Trend (2023-2031)
 - 12.5 Others
- 13 Middle East and Africa HUMIRA (Adalimumab Drug) Market
 - 13.1 Market Share by Country
 - 13.2 Saudi Arabia
 - 13.2.1 Historical Trend (2016-2022)
 - 13.2.2 Forecast Trend (2023-2031)
 - 13.3 United Arab Emirates
 - 13.3.1 Historical Trend (2016-2022)
 - 13.3.2 Forecast Trend (2023-2031)
 - 13.4 Nigeria
 - 13.4.1 Historical Trend (2016-2022)
 - 13.4.2 Forecast Trend (2023-2031)
 - 13.5 South Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.5.1 Historical Trend (2016-2022)
- 13.5.2 Forecast Trend (2023-2031)
- 13.6 Others
- 14 Global HUMIRA (Adalimumab Drug) Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 SWOT Analysis
 - 14.3 Drug Adoption Parameters
 - 14.4 Porter's Five Forces Model
 - 14.5 Key Demand Indicators
 - 14.6 Key Price Indicators
 - 14.7 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 AbbVie Inc.
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications
 - 15.2 Amgen Inc.
 - 15.2.1 Company Overview
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Fresenius Kabi AG
 - 15.3.1 Company Overview
 - 15.3.2 Product Portfolio
 - 15.3.3 Demographic Reach and Achievements
 - 15.3.4 Mergers and Acquisitions
 - 15.3.5 Certifications
 - 15.4 Celltrion Healthcare Co Ltd
 - 15.4.1 Company Overview
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
 - 15.5 Alvotect Ehf.
 - 15.5.1 Company Overview
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
 - 15.6 Bio-Thera Solutions Ltd.
 - 15.6.1 Company Overview
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.6.5 Certifications
- 15.7 Zydus Lifesciences Limited
 - 15.7.1 Company Overview
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 15.8 Hetero Healthcare Ltd.
 - 15.8.1 Company Overview
 - 15.8.2 Product Portfolio
 - 15.8.3 Demographic Reach and Achievements
 - 15.8.4 Mergers and Acquisitions
 - 15.8.5 Certifications
- 15.9 Innovent Biologics, Inc.
 - 15.9.1 Company Overview
 - 15.9.2 Product Portfolio
 - 15.9.3 Demographic Reach and Achievements
 - 15.9.4 Mergers and Acquisitions
 - 15.9.5 Certifications
- 15.10 Novartis International AG (Sandoz)
 - 15.10.1 Company Overview
 - 15.10.2 Product Portfolio
 - 15.10.3 Demographic Reach and Achievements
 - 15.10.4 Mergers and Acquisitions
 - 15.10.5 Certifications
- 15.11 Reliance Life Sciences Pvt. Ltd.
 - 15.11.1 Company Overview
 - 15.11.2 Product Portfolio
 - 15.11.3 Demographic Reach and Achievements
 - 15.11.4 Mergers and Acquisitions
 - 15.11.5 Certifications
- 15.12 Samsung C&T Corporation
 - 15.12.1 Company Overview
 - 15.12.2 Product Portfolio
 - 15.12.3 Demographic Reach and Achievements
 - 15.12.4 Mergers and Acquisitions
 - 15.12.5 Certifications
- 15.13 Terumo Corp.
 - 15.13.1 Company Overview
 - 15.13.2 Product Portfolio
 - 15.13.3 Demographic Reach and Achievements
 - 15.13.4 Mergers and Acquisitions
 - 15.13.5 Certifications
- 15.14 Torrent Pharmaceuticals Ltd.
 - 15.14.1 Company Overview
 - 15.14.2 Product Portfolio
 - 15.14.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.14.4 Mergers and Acquisitions
- 15.14.5 Certifications
- 16 Pricing Models and Strategies (Additional Insight)
 - 16.1 Cost Model
 - 16.1.1 Manufacturing Cost Analysis
 - 16.1.2 Procurement Cost Analysis
 - 16.2 Pricing Strategies
 - 16.2.1 Competitor Pricing Analysis
 - 16.2.2 Key Assessment of Product Attributes
 - 16.2.3 Pricing Benchmark
- 17 Global HUMIRA (Adalimumab) Drug Market- Distribution Model (Additional Insight)
 - 17.1 Overview
 - 17.2 Potential Distributors
 - 17.3 Key Parameters for Distribution Partner Assessment

Global HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

Market Report | 2023-04-16 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|---------------------|-----------|
| | Single User License | \$5999.00 |
| | Five User License | \$7999.00 |
| | Corporate License | \$9999.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2025-05-12"/> |
| | | Signature | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com